Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,155 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
SARS-CoV2-specific Humoral and T-cell Immune Response After Second Vaccination in Liver Cirrhosis and Transplant Patients.
Ruether DF, Schaub GM, Duengelhoef PM, Haag F, Brehm TT, Fathi A, Wehmeyer M, Jahnke-Triankowski J, Mayer L, Hoffmann A, Fischer L, Addo MM, Lütgehetmann M, Lohse AW, Schulze Zur Wiesch J, Sterneck M. Ruether DF, et al. Among authors: mayer l. Clin Gastroenterol Hepatol. 2022 Jan;20(1):162-172.e9. doi: 10.1016/j.cgh.2021.09.003. Epub 2021 Sep 9. Clin Gastroenterol Hepatol. 2022. PMID: 34509643 Free PMC article.
SARS-CoV-2 specific cellular response following COVID-19 vaccination in patients with chronic lymphocytic leukemia.
Mellinghoff SC, Robrecht S, Mayer L, Weskamm LM, Dahlke C, Gruell H, Vanshylla K, Schlösser HA, Thelen M, Fink AM, Fischer K, Klein F, Addo MM, Eichhorst B, Hallek M, Langerbeins P. Mellinghoff SC, et al. Among authors: mayer l. Leukemia. 2022 Feb;36(2):562-565. doi: 10.1038/s41375-021-01500-1. Epub 2021 Dec 22. Leukemia. 2022. PMID: 34937858 Free PMC article. No abstract available.
SARS-CoV-2-specific cellular response following third COVID-19 vaccination in patients with chronic lymphocytic leukemia.
Mellinghoff SC, Mayer L, Robrecht S, Weskamm LM, Dahlke C, Gruell H, Schlotz M, Vanshylla K, Schloser HA, Thelen M, Fink AM, Fischer K, Klein F, Addo MM, Eichhorst B, Hallek M, Langerbeins P. Mellinghoff SC, et al. Among authors: mayer l. Haematologica. 2022 Oct 1;107(10):2480-2484. doi: 10.3324/haematol.2022.280982. Haematologica. 2022. PMID: 35734927 Free PMC article. No abstract available.
Stabilized recombinant SARS-CoV-2 spike antigen enhances vaccine immunogenicity and protective capacity.
Meyer Zu Natrup C, Tscherne A, Dahlke C, Ciurkiewicz M, Shin DL, Fathi A, Rohde C, Kalodimou G, Halwe S, Limpinsel L, Schwarz JH, Klug M, Esen M, Schneiderhan-Marra N, Dulovic A, Kupke A, Brosinski K, Clever S, Schünemann LM, Beythien G, Armando F, Mayer L, Weskamm ML, Jany S, Freudenstein A, Tuchel T, Baumgärtner W, Kremsner P, Fendel R, Addo MM, Becker S, Sutter G, Volz A. Meyer Zu Natrup C, et al. Among authors: mayer l. J Clin Invest. 2022 Dec 15;132(24):e159895. doi: 10.1172/JCI159895. J Clin Invest. 2022. PMID: 36301637 Free PMC article.
MVA-based vaccine candidates encoding the native or prefusion-stabilized SARS-CoV-2 spike reveal differential immunogenicity in humans.
Mayer L, Weskamm LM, Fathi A, Kono M, Heidepriem J, Krähling V, Mellinghoff SC, Ly ML, Friedrich M, Hardtke S, Borregaard S, Hesterkamp T, Loeffler FF, Volz A, Sutter G, Becker S, Dahlke C, Addo MM. Mayer L, et al. NPJ Vaccines. 2024 Jan 26;9(1):20. doi: 10.1038/s41541-023-00801-z. NPJ Vaccines. 2024. PMID: 38278816 Free PMC article.
Hybrid immunity to SARS-CoV-2 in patients with chronic lymphocytic leukemia.
Mellinghoff SC, Robrecht S, Sprute R, Mayer L, Weskamm LM, Dahlke C, Gruell H, Teipel F, Schlößer HA, Siepmann K, Thelen M, Fink AM, Fischer K, Klein F, Addo MM, Kolovou A, Cornely OA, Eichhorst B, Hallek M, Langerbeins P. Mellinghoff SC, et al. Among authors: mayer l. Eur J Haematol. 2024 May;112(5):788-793. doi: 10.1111/ejh.14170. Epub 2024 Feb 4. Eur J Haematol. 2024. PMID: 38311570
Safety, immunogenicity, and optimal dosing of a modified vaccinia Ankara-based vaccine against MERS-CoV in healthy adults: a phase 1b, double-blind, randomised placebo-controlled clinical trial.
Raadsen MP, Dahlke C, Fathi A, Hardtke S, Klüver M, Krähling V, Gerresheim GK, Mayer L, Mykytyn AZ, Weskamm LM, Zoran T, van Gorp ECM, Sutter G, Becker S, Haagmans BL, Addo MM; MVA-MERS-S_DF-1 Study group. Raadsen MP, et al. Among authors: mayer l. Lancet Infect Dis. 2024 Oct 7:S1473-3099(24)00423-7. doi: 10.1016/S1473-3099(24)00423-7. Online ahead of print. Lancet Infect Dis. 2024. PMID: 39389076
1,155 results